Anthem Biosciences Limited
Founded in 2006, Anthem Biosciences Ltd provides integrated CRDMO services and specializes in manufacturing specialty ingredients, focusing on both New Chemical Entities and New Biological Entities, with platforms like RNA interference and Antibody-Drug Conjugates.
What Anthem files
- Others29
- Investor Meet18
- Updates11
- Important6
- PPTs5
- Board Meeting4
Anthem Biosciences has scheduled its 20th Annual General Meeting. The company is ensuring all shareholders, even those without registered emails, can access its FY25-26 Annual Report online. This is being facilitated via a dispatched letter providing the web link.
Anthem Biosciences released its voluntary FY26 BRSR, highlighting significant R&D (14%) and Capex (51%) for sustainability and technology. The CRDMO business exports 85% of revenue. The company achieved zero safety incidents and improved GHG intensity. Supply chain sourcing from India notably increased to 85%.
Anthem Biosciences' Board approved an Upside Sharing Arrangement, subject to shareholder vote. An investor's share divestment yielded 1317.0 Cr, with 127.68 Cr slated for promoters. This arrangement is a key development.
Anthem Biosciences amended a loan agreement with its wholly-owned subsidiary, Neoanthem. This allows converting an additional Rs. 275 Cr of the Rs. 550 Cr loan into Neoanthem's equity, boosting the subsidiary's capital base.
Anthem Biosciences reported two designated persons violated its insider trading code by selling shares totaling approx. 0.47 Cr during restricted periods or without pre-clearance. The company issued warning letters, ensuring stricter future compliance.